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ABSTRACT
Background and aims. Changes in single microRNA (MIR) expression have been associated 
with chemo-resistance in Biliary Tract Cancer (BTC). However, a global assessment of the 
dynamic role of the microRNome has never been performed to identify potential therapeutic 
targets that are functionally relevant in the BTC cell response to chemotherapy. 
Approach and Results. high-throughput-screening of 997 LNA-MIR-inhibitors was performed in 
6 CCA cell lines treated with Cisplatin-Gemcitabine (CG) seeking changes in cell viability. 
Validation experiments were performed with miRvana probes. MIR and gene expression was 
assessed by TaqMan-assay, RNA-sequencing and in-situ-hybridization in 4 indepedent cohorts of 
human BTC. Knock-out of microRNA was achieved by CRISPR-CAS9 in CCLP cells 
(MIR1249KO) and tested for effects on chemotherapy sensitivity in-vitro and in-vivo. 
High-throughput-screening revealed that MIR1249-inhibition enhanced chemotherapy sensitivity 
across all cell lines. MIR1249 expression was increased in 41% of cases in human BTC. In 
validation experiments, MIR1249-inhibition did not alter cell viability in untreated or DMSO-treated 
cells; however it did increase CG effect. MIR1249 expression was increased in CD133+ biliary A
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cancer cells freshly isolated from the stem niche of human BTC, as well as in CD133+ chemo-
resistant CCLP cells. MIR1249 modulated the chemotherapy-induced enrichment of CD133+ 
cells by controlling their clonal expansion via the Wnt-regulator FZD8. MIR1249KO cells had 
impaired expansion of the CD133+ subclone and its enrichment after chemotherapy, reduced 
expression of Cancer-Stem-Cell markers, and increased chemosensitivity. MIR1249KO xenograft 
BTC models showed tumour shrinkage after exposure to weekly CG, while WT models showed 
only stable disease over treatment. 
Conclusions. MIR1249 mediates resistance to CG in BTC and may be tested as a novel target 
for therapeutics.
Introduction
Biliary tract cancers (BTC) include cholangiocarcinoma (CCA) and gallbladder cancer (GBC) and 
their incidence is increasing worldwide (1-4). Lack of effective radical treatments and rapid failure 
of palliative ones highlight the need for a better understanding of BTC biology and mechanisms of 
response to treatment (2, 5). Eighty-percent of BTC patients present at an advanced stage, 
when treatment options are limited to chemotherapy with cisplatin and gemcitabine (CG)(5). Only 
11% of patients gain a long-term benefit from chemotherapy, while primary resistance is detected 
in 20% of patients (6). Most patients develop secondary resistance after an initial response or 
stabilization of the disease, which is responsible for a global median overall survival shorter than 
12 months. Several mechanisms of chemo-resistance may act synergistically and drive cancer 
cells to escape biochemical inhibition or cell death caused by chemotherapy (7). Acquisition of 
stemness features in cancer cells appears to be a driver of resistance that is common with other 
tumour types (8, 9). 
MicroRNAs (miRNA) are small non-coding-RNAs controlling mRNA expression (10). We and 
others demonstrated that miRNAs are aberrantly expressed in BTC and promote biliary 
carcinogenesis (11-19). Despite growing evidence that links single miRNAs with chemo-
resistance, no comprehensive genome-wide approach has been undertaken to date to assess the 
functional role of miRNAs in the cellular dynamics involved in drug response in BTC. It is known 
that chemo-resistant is a peculiar feature of BTC that is responsible for the poor prognosis of 
these patients. Thus, in these studies we have investigated the functional role of microRNA 
inhibitors in mediating drug response in chemotherapy-treated BTC cells, using a highthroughput 
approach that investigates the inducible role of miRNAs in response to cancer drugs.A
cc
ep
te
d 
A
rt
ic
le
© 2020 The Authors Hepatology published by Wiley Periodicals, Inc. on behalf of American 
Association for the Study of Liver Diseases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Experimental porcedures
Human tissues. The human BTC tissues were collected under approval of the Ethical Committee 
for Clinical Research at 3 independent Institutions, the Humanitas Research Hospital 
(#21072014; cohort 1), the Royal Marsden hospital (RMH) (CCR 4415; cohort 2), and  the 
University Hospital of Padua (#0010416; cohort 3). The study protocols conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki, as per ethical approval given by Institutional 
Review Board. Formalin Fixed Paraffin Embedded (FFPE) tissues were retrieved and RNA was 
extracted from the tumour and the matched non tumour component after microscopic dissection 
by using the Ambion RecoverAll kit (Thermofisher Waltham, Massachusetts, USA). Relapse-Free 
Survival (RFS) was used as end point of the study. Disease recurrence was defined as the 
presence of imaging-proven disease. 
Highthroughput-screening (HTS). A human LNA microRNA inhibitor library (miRCURY LNA, 
version 3; #190102-3) was purchased from Exiqon (Life Technologies, Paisley, UK). The library 
was distributed across 15 x 96-well plates (Greiner Bio-One, Frickenhausen, Germany) in a 
volume of 5 ul each well. Each plate included two negative controls (LNA negative A, LNA 
negative B from Exiqon) and positive controls (AllStars-Hs-Positive cell death phenotype control, 
SI04381048 from Qiagen, Manchester, UK). Fifteen ul of transfecting solution with medium and 
Hiperfect (PN301705, Qiagen, Manchester, UK) was added to each well. Thirty μl of cell solution 
was then added to each well to have a final concentration of 10,000 cells and 50nM of miRNA 
inhibitors. A column with no cells (x 8) was added in one plate. Forty-eight hours later, 50 ul of a 
combination of cisplatin (C) (232120, Sigma-Aldrich, Gillingham, UK) and gemcitabine (G) 
(1288463-200MG, Sigma-Aldrich, Gillingham, UK) diluted in media were added. Cisplatin was 
dissolved in sterile PBS and stocked at a concentration of 1 mg/ml (3mM). Gemcitabine was 
diluted in DMSO and stocked at a concentration of 10mg/ml (30mM). Both stocks would then be 
diluted in media to achieve a final solution that would always contain less than 0.001% of DMSO. 
Cell viability was measured 72 hours later by CellTiter-Blue® Assay (Promega, Madison, WI, 
USA). The cell viability measurement from each hit was normalized to that of the averaged 
negative controls across the respective plate. Each cell line was tested in triplicate. Statistical 
significance (p<=0.05) was determined by two-sided t-test across 3 replicates. 
MIR1249-KO generation through CRISPR-CAS9. CCLP-1 cells were transfected by using 
Lipofectamine 3000 reagent (Thermofisher, Waltham, MA, USA) with the CRISPR vector pCAS-
Guide-EF1a-GFP CRISPR Vector (GE100018, OriGene Technologies, Inc. MD USA) expressing 
gRNAs containing the inserted target sequence for miR1249. Target sequences of the gRNA 
were as follows: gRNA3 5’ CGTCGGTCGTGGTAGATAGG 3’; gRNA4 5’ A
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AATCTCGACCGGACCTCGAC 3’). Forty-eight hours later GFP positive cells were sorted with a 
FACSAria-II (BD Biosciences, San Jose, CA, USA) and maintained in culture. Genome editing 
was verified at day 17 using the Indel identification kit (Clontech Biotec., Mountain View, CA, 
USA). Cells were enriched for the edited clones by performing serial dilution. Final assessment of 
the successful genome editing was performed by sequencing and real time PCR.
Statistical analyses. Statistical analyses were performed by GraphPad Prism 6 (La Jolla, CA, 
USA).  Results are expressed as mean ± SD, unless indicated otherwise. Groups were compared 
with either a 2-tailed Student’s t test (for analysis of 2 groups) or using 1-way ANOVA to compare 
multiple groups. Significance was accepted when p was less than 0.05.
Results
Highthroughput functional studies and characterization of human cancer tissues identified 
MIR1249 inhibition as a clinically relevant strategy to increase chemo-sensitivity in human 
BTC. Highthroughput screening (HTS) technologies were applied to screen a panel of 6 CG-
treated BTC cell lines against a library of Locked-Nucleic-Acid (LNA) miRNA inhibitors. Growth 
Inhibitory (GI)50 concentration for cisplatin and gemcitabine was derived for each cell line to 
define the concentration at which the combination of CG could induce cytotoxicity without 
reducing cell viability by more than 50%, in order to enable identification of sensitizers (Suppl 
Figure 1). HTS was run in triplicate in each cell line (Suppl Table 1). Inhibition of MIR148a and 
members of the let-7 family reduced sensitivity in a number of cell lines, in line with published 
literature (13, 20). Eleven miRNA-inhibitors acted as sensitizers in all intrahepatic CCA (iCCA) 
cells, while 4 in all extrahepatic CCA (eCCA) cells (p<0.05) (Figure 1A). Inhibitors of MIR1249, 
MIR133b, MIR1247 and MIR1228 decreased cell viability across all cell lines in comparison to 
CTRL inhibitors. The tissue expression of these four shortlisted miRNAs was determined in 
human BTCs by Taqman assay to investigate the clinical relevance of these candidates. 
MIR133b, MIR1247 and MIR1228 expression was not increased in the tumour tissue in 
comparison to matched adjacent non tumour tissue (Cohort 1, n=29) (Suppl Figure 2A). 
Conversely, MIR1249 was over-expressed in the tumour compartment in comparison to paired 
non tumour tissue in 32% of cases (Figure 1B). Interestingly, when the cohort was split according 
to median MIR1249 tumour expression, cases with high expression were associated with worse 
prognosis independently of adjuvant chemotherapy (Figure 1C, Suppl Table 2). At multivariate 
analysis (considering T stage, N stage, adjuvant chemotherapy and MIR1249 tumour expression) 
adjuvant treatment (HR 0.70; p<0.001) and MIR1249 expression (HR 0.65; p: 0.004) maintained 
an independent prognostic value. An increase of MIR1249 expression by Taqman assay was A
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observed in 53% of cases of a separate cohort (cohort 2, n=28) (Suppl Figure 2B). When cohort 1 
and 2 were pooled together 41% of cases showed increased MIR1249 expression in the tumour. 
RNA-sequencing data confirmed over-expression of MIR1249 in the tumour tissue in comparison 
to paired normal tissue in 55% of cases (TCGA cohort (21), n=9) (Suppl Figure 2C). Kaplan Meier 
analysis of the whole TCGA cohort showed that tumour MIR1249 expression was again 
associated to progression free interval (PFI) (Suppl Figure 2D). When assessed by in situ 
hybridization, MIR1249 was strongly positive in 53% of tumour cases and was statistically 
associated with lower survival outcome (cohort 3, n= 28) (Figure 1D-E, Suppl Table 3). 
Validation functional studies identified the involvement of MIR1249 in driving a 
chemotherapy-specific reactive response in cancer cells. On the basis of the clinical and 
biological relevance of these data, MIR1249 was selected as a candidate for further studies. 
MIR1250 inhibitor (that provided no effect in any of the cells in the HTS) was included in the 
validation phase as a negative control, along with scrambled control (Suppl Figure 2E). Using 
alternative probes for miRNA inhibition, the ability of MIR1249 inhibitor to enhance BTC cell 
response to CG chemotherapy was validated. Interestingly, we did not observe a cytotoxic effect 
for MIR1249 inhibitor in absence of chemotherapy treatment (Figure 2), suggesting that MIR1249 
interferes with a chemotherapy-specific response. Indeed, MIR1249 expression was increased as 
a response to CG treatment in human CCA cells (Suppl Figure 2F). Enrichment of resistant cells 
expressing stem cell markers is known to occur in response to chemotherapy treatment in a 
variety of cancers (22, 23). Thus, we hypothesized that MIR1249 inhibition can increase chemo-
sensitivity by limiting the expansion of this resistant sub-population. In order to verify our 
hypothesis, we assessed the expression of MIR1249 in human BTC spheroids generated from 
human cells freshly extracted from the stem niche of BTC samples, before and after selection for 
surface cell markers (Figure 3A). MIR1249 expression was increased in BTC cells compared to 
non-cancer biliary tract stem cells (BTSC). CD133+ and CD13+ cells had increased expression of 
MIR1249 compared to CD133- and CD13- cells (Figure 3A). CD133 has been consistently 
reported to be a marker of chemo-resistant cancer cells which are enriched after treatment (22-
27), and CD133+ BTC cells were shown to be tumorigenic and express features of cancer stem 
cells (9, 28). Therefore, we speculated that MIR1249 could affect chemo-resistance by inducing 
the expansion of CD133+ BTC cells. Indeed, an association between CD133 positivity and 
MIR1249 strong expression was observed in human BTC tissues (Suppl Figure 2G). Increased 
MIR1249 expression was confirmed in CCLP-1 CD133+ cells sorted from 2D cultures both by 
Taqman assays and ISH (Figure 3B). CD133+ cells gave rise to spheroids, indicating their self-
renewal properties (Figure 3B-C) and were more resistant to CG chemotherapy, when cultured in A
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2D (Suppl Figure 2H) or 3D (Figure 3C&D), in comparison to CD133- cells. Inhibition of MIR1249 
in CD133+ CCLP-1 cells increased sensitivity in comparison to CTRL microRNA inhibitor, while 
MIR1249 enforced expression in CD133- cells reduced sensitivity to CG chemotherapy (Figure 
4A, Suppl Figure 2I). In order to understand the potential of MIR1249 to control the expansion of 
CD133+ cells, we studied the fraction of CD133+ cells in the presence and absence of MIR1249 
modulation. Enforced expression of MIR1249 in BTC cells expanded the proportion of CD133+ 
sub-population (Figure 4B), which had increased expression of stem cell markers (Figure 4C). 
Indeed, CSC markers were increased in CD133+ vs CD133- cells, and after transfection with 
MIR1249 mimic compared to mimic control (Figure 4C). Conversely, inhibition of MIR1249 
reduced the CG-induced enrichment of CD133+ cells (Figure 4D). To confirm the role of MIR1249 
in the expansion of CD133+ cells, we generated a MIR1249KO CCLP-1 cell line using CRISPR-
CAS9 technologies (Suppl Fig 3A&B&C). MIR1249KO cells were more sensitive to CG treatment 
with a concentration-response effect (Fig 4E) and showed impaired expansion of CD133+ cells 
(Suppl Fig 3D & Figure 4F), along with reduced expression of cancer stem cell (CSC) marker 
(Suppl Fig 3E) and lack of spheroid formation (Suppl Fig 3F). Reintroduction of MIR1249 in 
MIR1249KO cells restored chemoresistance in CCLP-1 cells (Fig 4G & Suppl Fig 3G).
MIR1249 drives clonal expansion of CD133+ cells by re-wiring the Wnt pathway activation. 
In order to identify the mechanisms through which MIR1249 mediates chemo-resistance, we 
characterized the gene expression profiles of chemotherapy-treated CCLP-1 cells after inhibition 
of MIR1249.  Pathway analysis of the deregulated genes showed that MIR1249 inhibition induced 
changes in the same pathways that were deregulated by chemotherapy. We noticed an 
enrichment of deregulated genes in the Wnt pathway in both comparisons (chemotherapy vs 
vehicle; MIR1249 inhibition vs no inhibition), suggesting that MIR1249 inhibition may act on the 
Wnt pathway to restore chemotherapy sensitivity in BTC cells (Suppl Fig 3H&I). In line with this 
hypothesis, Wnt deregulation was previously found to drive proliferation of chemo-refractory CSC 
(29, 30). PANTHER pathway analysis of the predicted targets of MIR1249 based on DIANA 
software showed an enrichment of Wnt signalling (fold enrichment 1.41; p:9.1E-03). In silico 
analyses revealed, amongst others, frizzled class receptor 8 (FZD8) as a potential mRNA target 
of MIR1249 (Suppl Fig 3L). Previous evidence suggests that FZD8 can act as a negative 
regulator of the canonical Wnt pathway by activating the non-canonical Wnt/Ca++ signalling (31-
34). Thus, we hypothesized that MIR1249 mediates the expansion of CD133+ cells by acting on 
FZD8. Indeed, FZD8 was significantly reduced in CD133+ in comparison to CD133- cells and 
was associated with inactivation of the non-canonical Wnt and activation of the canonical Wnt 
pathway (Fig 5A&B). FZD8 protein expression was reduced in CD133- cells transfected with A
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MIR1249 mimic in comparison to control (CTRL) mimic (Figure 5A), and a luciferase reporter test 
confirmed a direct interaction between MIR1249 and the 3’UTR of FZD8 (Figure 5C). In human 
BTC samples (cohort 3) there was a significant inverse relation between MIR1249 and FZD 
expression (Fisher exact test p:0.004; Suppl Fig 3N). Inhibition of FZD8 recapitulated the 
phenotype induced by MIR1249 mimic (Figure 5D&E&F). MIR1249KO cells had increased 
activation of the non-canonical Wnt pathway (Fig 5G&H, Suppl Fig 3M and Suppl Table 4) and 
FZD8 inhibition in these cells partially increased resistance to CG (Fig 5I). 
In-vivo validation of the MIR1249-dependent chemo-resistance in murine tumours bearing 
disruption of MIR1249. MIR1249KO cells had reduced in-vivo tumorigenicity, confirming the role 
of MIR1249 in driving the expansion of CSC (Figure 6A, Suppl Fig S4A). Chemotherapy 
sensitivity was increased in mice bearing MIR1249KO tumour xenografts. Indeed, the weekly 
combination of CG could induce tumour shrinkage in MIR1249KO xenografts while determined 
only tumour stabilization in wild type (WT) xenografts (Figure 6B&C&D, Suppl Table 5). The 
chemotherapy schedule was well tolerated with only minimal changes in weights for CG-treated 
mice at the end of the treatment course. No differences in weights were observed between WT 
and MIR1249KO CG-treated mice, suggesting that the drug exposure was comparable amongst 
the two groups (Figure 6E). In addition, no differences in liver and kidney toxicity were observed 
between WT and MIR1249KO mice when treated with CG (Suppl Fig4B&C). To confirm the role 
of MIR1249 in driving the expansion of CD133+ cells via FZD8 we assessed protein expression 
in explanted tumours from MIR1249KO vs WT xenograft (either treated with CG and vehicle) and 
observed that MIR1249KO tumours showed lack of MIR1249 expression and reduced expression 
of CD133, with increase in FZD8 expression (Figure 6F).    
Discussion
Therapeutic development for BTC remains an unmet need. Chemotherapy does represent the 
main backbone for advanced biliary cancers (ABC) treatment even though the response rate 
observed in ABC patients does not exceed 25%. Novel strategies aimed at improving the efficacy 
of chemotherapy might prove beneficial to a large proportion of ABC patients. The field of miRNA-
based therapeutics has recently expanded and entered the phase of clinical investigation (10, 35, 
36). The ability of miRNAs to target multiple pathways is attractive as it may prevent the onset of 
compensatory pathways.
Data from the MesomiR1 trial have shown the feasibility of a therapeutic approach based on 
miRNA replacement in human cancer patients (37). However, this approach holds two major A
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limitations: 1) toxicity related to the immuno-stimulatory effects of encapsulating delivery systems, 
and 2) off-target effects induced by a disproportionally high level of miRNA in the cellular system. 
Conversely, an approach based on the inhibition of miRNAs would reduce the risk of off-target 
effects by impacting on the physiological level of a miRNA rather than introducing a perturbation 
that affects cellular homeostasis.  Recent technologies have enabled chemical modifications of 
anti-miRs (i.e. addition of LNA) that increase their stability (38), allowing the clinical investigation 
of this therapeutic strategy in cancer patients (NCT02580552).  In these studies, we have 
identified MIR1249 as a miRNA that drives the emergence of chemo-resistance by acting on the 
CD133+ cell population. While we usually observe tumour stabilization with chemotherapy in BTC 
patients, our data suggest that the addition of MIR1249 inhibition to CG can increase tumour 
responses in-vivo. It is known that partial responses are associated with prolonged life 
expectancy in BTC patients, and therefore we speculate that treatment with MIR1249 inhibitors 
might prove beneficial to impact on survival of BTC patients by preventing primary resistance and 
delaying the onset of secondary resistance. It has been shown already that the canonical WNT/β-
catenin signaling mediates self-renewal of stem cells, while non-canonical WNT signaling 
pathways is involved in maintenance of stem cells, cell plasticity and inhibition of the canonical 
WNT signaling cascade (29), supporting our data that MIR1249 can drive maintenance and 
expansion of CSC through regulation of the non-canonical Wnt pathway. With regards to FZD8, 
data in the literature are so far contradictory, with some reports showing the capacity of FZD8 to 
stimulate malignant transformation of cancer cells (39), and others showing its involvement in 
reducing tumour initiating capacity (32). In line with our data that showed low expression of FZD8 
in CSC, analysis of the ATLAS datasets showed unfavorable prognosis in cases of pancreatic 
cancers with low FZD8 expression. Nonetheless, the attempts to therapeutically inhibit FZD8 
have failed so far lack of therapeutic index, suggesting that FZD8 may not be involved in 
promoting cancer growth.
Last, to our knowledge, this is the first time the combination of CG has been given in a weekly 
schedule to BTC mouse models in an attempt to better mimic the schedule used in the ABC-02 
trial which licensed the combination CG for standard clinical practice. We noticed good tolerance 
of this schedule and suggest that this regimen should be used in the future in in-vivo BTC 
modelling in order to increase clinical relevance of pre-clinical findings.
In conclusion, we have provided evidence for a potential target to be taken forward in the 
therapeutic development. From our data MIR1249 is involved in the chemotherapy resistance in 
all different subtypes of CCA, and therefore we would suggest testing MIR1249 inhibitor in a trial 
including ABC. In addition, it may be speculated that this mechanism may be shared with other 
cancer types as well, and therefore investigation in other solid tumours may be warranted.A
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Figures legend
Figure 1. MIR1249 represents a clinically significant candidate for therapeutics based on 
in-vitro HTS data and expression profiles of human BTC samples. (A) Hightroughput 
screening technologies were applied to 6 cell lines in triplicate. Cells were reverse transfected 
with LNA miRNA inhibitors for 48 hours followed by treatment with CG chemotherapy (see also 
Figure S1).  After 72 hours cell viability was assessed by Cell-Titer blue assay. Each square 
indicates logarithmic value of the mean of cell viability normalized to averaged negative controls 
(N=3), with color code indicating the degree of change in cell viability. Here we show miRNA 
inhibitors which were significant (p<0.05) in enhancing chemosensitivity across all iCCA or across 
all eCCA (p<0.05). * indicates miRNA inhibitors that were significant across all 6 cell lines (see 
also Table S1). (B) MIR1249 expression was assessed by Taqman assay in the tumour (TT) and 
adjacent tissue (AT) of 29 human clinically annotated BTC samples (cohort 1) (see also Table 
S2). Insufficient RNA quality was achieved for the AT of one case, thus data for 28 cases are 
shown. Bars represent mean values of 2 technical replicates for each patient. Purple, yellow and 
green bars indicate iCCA, eCCA and GBC respectively. (C) Kaplan Meier analysis was used to 
correlate relapse free survival (RFS) with MIR1249 tumour tissue expression. Cases were 
classified in low and high MIR1249 expression according to the median value. (D) MIR1249 
expression was assessed by ISH in 28 FFPE human BTC tissues (cohort 2). Representative 
pictures are shown (see also Table S3). Original magnifications 10X (left) and 20X (right). (E) 
Kaplan Meier curves in cohort 2 with respect to MIR1249 expression (strong: ISH score 2+ or 
greater; neg/mild: ISH score 0 or 1+).A
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Figure 2. MIR1249 inhibition decreases cell viability in chemotherapy-treated cells only. (A) 
MIR1249 inhibition was achieved using miRvana inhibitory probes. Cells were plated in 96 well 
plates and transfected with the indicated probes for 48 hours before being treated with DMSO or 
CG for further 72 hours. Cell Death CTRL was used as a positive control. Cell viability was 
assessed by CellTiter blue assay. Bars indicate mean of 6 independent experiments +/- standard 
deviation (SD).
Figure 3. Human CD133+ BTC cells hold high MIR1249 levels and are highly chemo-
resistant. (A)  Cancer stem cell niche of human BTC samples was identified, cells were then 
extracted, sorted by cell surface markers and cultured in 3D spheroids. MIR1249 expression was 
assessed by Taqman assay. Bars indicate 3 independent replicates +/- SD. BTSC: Biliary Tract 
Stem Cells. (B) CCLP-1 cells were sorted by FACS for CD133 surface expression. MIR1249 was 
assessed both by Taqman (blue bars indicating mean of three independent experiments +/-SD) 
and by ISH (representative pictures are shown, scale bar: 100μM). (C) When cultured in ultra-low 
attachment plates (ULA) CD133+ cells formed large and defined 3D spheroids conversely to 
CD133- cells. (C) CCLP-1 cells were sorted for CD133 surface expression and cultured in ULA 
plates. After 5 days baseline imaging of spheroids by Celigo showed reproducible spheroid 
formation across the plates, even though CD133- spheroids were smaller. After 3 days of CG 
treatment (scalar concentrations up to 3M cisplatin and 30nM gemcitabine) CD133- spheroids 
shrank in volume, while CD133+ spheroids did not, even at the highest CG concentration. Bars 
represent mean of 6 replicates +/- SD. (D) Representative pictures of spheroids with and without 
CG treatment. Spheroids were monitored up to 6 days. CD133- spheroids volume reduced from 
baseline, while CD133+ spheroids volume was stabilized (see also Figure S2).
Figure 4. MIR1249 inhibition prevents chemotherapy-induced enrichment of CD133+ sub-
clone. (A) CCLP-1 cells were transfected with indicated probes after being sorted for CD133 
surface expression. Mock indicates absence of any probe. Chemotherapy was added 48 hours 
after transfection, and cell viability read 72 hours later by CellTiter Blue assay. Bars indicate 
mean of 6 independent experiments +/- SD. (B) BTC cells were transfected and assessed for 
CD133+ by FACS. The population of CD133+ cells increased with enforced expression of 
MIR1249. Bars indicate mean of 3 independent experiments +/- SD. Representative pictures of A
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the FACS analysis are shown; CD133+ cells are identified by the double positivity of APC-A and 
GFP-A (right upper quadrant). (C) BTC cells were sorted for CD133 and collected for RNA 
extraction. Bars represent LOG value of the indicated ratio with the relative control (positive 
values above the x-axis indicate increase in expression vs relative control). All markers are 
increased in CD133+ (vs CD133-) cells and after transfection of unsorted cells with MIR1249 
mimic (vs mimic control). Bars indicate mean of at least four independent replicates +/- SE. * p < 
0.05; ** p < 0.01; *** p < 0.001 vs relative control. (D) CCLP-1 cells were treated with DMSO or 
CG chemotherapy after transfection with CTRL or MIR1249 inhibitor and assessed for CD133+ 
by FACS. CG induced enrichment of CD133+ cells, and this enrichment was reduced in case of 
transfection with MIR1249 inhibitor. Bars represent mean of 3 independent experiments +/- SD. 
Representative pictures of FACS analysis are shown on the right. Pink dots represent CD133+ 
cells. (E) WT and MIR1249KO CCLP-1 cells were treated with DMSO and CG chemotherapy at 
scalar doses up to 5M cisplatin and 50nM gemcitabine. Bars represent the log of the ratio 
between CG- and DMSO-treated cells. Bars indicate mean of 6 independent experiments +/- SD. 
(F) WT and 2 clones of MIR1249KO cells were treated with DMSO and CG chemotherapy and 
assessed for CD133 expression by FACS. Bars represent mean of three independent 
experiments +/- SD. (G) Cells were transfected with CTRL mimic or MIR1249 mimic and treated 
with DMSO and CG chemotherapy. Bars represent mean of 6 independent experiments +/- SD. 
*** p < 0.001 (see also Figure S3).
Figure 5. MIR1249 activates the Wnt pathway by acting on FZD8. (A) CCLP-1 cells were 
sorted for CD133 expression and processed for western blotting analysis (left side). CD133- cells 
were also transfected with the indicated probes for 48 hours before proceeding to western blotting 
(right side). (B) CCLP-1 cells were sorted and transfected with NFAT and TOP-FLASH vector for 
48 hours before luciferase activity was recorded. Bars indicate mean of 6 independent 
experiments +/- SD. Two-way anova test <0.05. (C) BTC cells were transfected with pMIR-3UTR-
FZD8 vector +/- MIR1249 mimic and luciferase activity recorded. Bars indicate mean of 6 
independent experiments +/- SD.  (D) BTC cells were transfected for 48 hours and positivity for 
CD133 assessed by FACS. Bars represent mean of three independent experiments +/- SD. (E) 
CCLP-1 (left) and TFK-1 (right) cells were transfected with siFZD8 or siCTRL for 48 hours and 
collected for mRNA expression by Taqman. Bars represent log value of the ratio between siFZD8 
and siCTRL. Bars indicate mean of three independent experiments +/- SD. * p < 0.05; ** p < 0.01; 
*** p < 0.001. (F) CG-treated BTC cells were transfected for 48 hours and positivity for CD133 
assessed by FACS. Bars represent mean of three independent experiments +/- SD. (G) CCLP-1 A
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cells were infected with the indicated vectors and treated with CG chemotherapy before being 
fixed in formalin and embedded in paraffin for IHC and ISH (see also Table S4). Scale bars: 
100μm. (H) Cells were transfected with NFAT or TOP-FLASH vectors and luciferase activity 
recorded after 48 hours. CD133+ cells were added as controls. Bars indicate mean of three 
independent experiments +/- SD. (I) CCLP-1 cells were transfected for 48 hours and treated with 
DMSO or increasing doses of CG (up to 5uM C and 50nM G). Bars represent the log value of the 
ratio between CG-treated and DMSO-treated cells. Bars indicate mean of 6 independent 
experiments +/- SD.
Figure 6. Lack of MIR1249 increases sensitivity to chemotherapy in-vivo. (A) WT or 
MIR1249KO CCLP-1 cells were injected subcutaneously in the flank of NSG mice (N=20 each) 
and monitored for growth by caliper (see also Figure S4). (B) At day 14 mice were randomized to 
be treated with a weekly combination of intraperitoneal gemcitabine (150 mg/kg) and cisplatin (2 
mg/kg) or vehicle alone for 3 weeks before being sacrificed. Data are presented normalized to 
baseline pre-treatment tumour size (day 14). Black * indicate p value < 0.05; grey * indicate p 
value between 0.05 and 0.085 (see also Table S5). (C) Representative pictures of five explanted 
tumours per group. (D) Explanted tumours of CG-treated were weighted before being stored for 
analyses. Error bars indicate mean with SE. (E) Mice were weighted periodically over the course 
of treatment. Bars represent mean of 10 mice +/- SD. * p < 0.05. (F) Representative pictures of 
MIR1249 ISH staining and IHC staining for the indicated proteins performed on the explanted 
tumours, along with quantitative analysis. Scale bars: 100μM. Three mice per group were 
analyzed (for a total of 12) and CG- and vehicle-treated tumours were grouped to assess the 
differences between KO and WT.
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